| 1 | Counterpoint: Natriuresis-Guided Diuresis in Patients Admitted to Hospital With Heart Failure – Barking Up the Wrong Tree? Towards Direct Insights Into the Efficacy of Diuretic Therapy | 0.9 | 3 | Citations (PDF) |
| 2 | European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society | 1.8 | 154 | Citations (PDF) |
| 3 | Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction | 3.0 | 22 | Citations (PDF) |
| 4 | Role of Rhythm Control With Antiarrhythmic Agents in Heart Failure With Preserved Ejection Fraction: Insights From the AFFIRM Trial 2025, 1, 4-12 | | 0 | Citations (PDF) |
| 5 | Effects of low vs. moderate intense resistance exercise training combined with endurance exercise training in patients with heart failure: a randomized clinical trial | 1.5 | 10 | Citations (PDF) |
| 6 | Meta-Analysis and Metaregression of the Treatment Effect of Intravenous Iron in Iron-Deficient Heart Failure | 3.0 | 16 | Citations (PDF) |
| 7 | Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study | 2.7 | 73 | Citations (PDF) |
| 8 | Feasibility of Continuous Noninvasive Pulmonary Artery Pressure Monitoring via the Cordella Implantable Pulmonary Artery Sensor | 3.0 | 3 | Citations (PDF) |
| 9 | Contemporary Diuretic Therapies for Acute Heart Failure: Time for a Desalination-Guided Approach? | 0.9 | 3 | Citations (PDF) |
| 10 | Response by Dauw and Mullens to Letters Regarding Article, “Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study” | 2.7 | 4 | Citations (PDF) |
| 11 | From Hospital to Home | 1.4 | 18 | Citations (PDF) |
| 12 | Self-Reported Sodium Intake and Sodium Vulnerability in Heart Failure With Preserved Ejection Fraction | 2.0 | 3 | Citations (PDF) |
| 13 | Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial | 2.7 | 27 | Citations (PDF) |
| 14 | Pulmonary involvement in transthyretin cardiac amyloidosis: a case report | 0.3 | 1 | Citations (PDF) |
| 15 | Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure | 2.0 | 9 | Citations (PDF) |
| 16 | Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice | 2.6 | 19 | Citations (PDF) |
| 17 | Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial | 2.6 | 50 | Citations (PDF) |
| 18 | Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial | 2.6 | 62 | Citations (PDF) |
| 19 | Acute heart failure: current pharmacological treatment and perspectives | 2.6 | 42 | Citations (PDF) |
| 20 | Incidence, Risk Assessment and Prevention of Sudden Cardiac Death in Cardiomyopathies | 4.7 | 34 | Citations (PDF) |
| 21 | 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy | 1.8 | 576 | Citations (PDF) |
| 22 | Electrical management of heart failure: from pathophysiology to treatment | 2.6 | 40 | Citations (PDF) |
| 23 | Acute and Chronic Exercise Training in Patients with Class II Pulmonary Hypertension: Effects on Haemodynamics and Symptoms | 1.9 | 2 | Citations (PDF) |
| 24 | The MADIT-ICD benefit score helps to select implantable cardioverter-defibrillator candidates in cardiac resynchronization therapy | 1.8 | 13 | Citations (PDF) |
| 25 | Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure
Association of the European Society of Cardiology | 4.7 | 135 | Citations (PDF) |
| 26 | The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the
IRON‐CRT
trial | 4.7 | 20 | Citations (PDF) |
| 27 | Safety and Efficacy of a Wireless Pulmonary Artery Pressure Sensor: Primary Endpoint Results of the SIRONA 2 Clinical Trial | 1.9 | 46 | Citations (PDF) |
| 28 | Acetazolamide in Decompensated Heart Failure with Volume Overload trial (
ADVOR
): baseline characteristics | 4.7 | 36 | Citations (PDF) |
| 29 | Electrical Dyssynchrony in Cardiac Amyloidosis: Prevalence, Predictors, Clinical Correlates, and Outcomes | 0.9 | 12 | Citations (PDF) |
| 30 | Ambulatory Haemodynamic-Guided Management Reduces Heart Failure Hospitalizations in a Multicentre European Heart Failure Cohort | 1.9 | 15 | Citations (PDF) |
| 31 | Ultrasound imaging of congestion in heart failure: examinations beyond the heart | 4.7 | 183 | Citations (PDF) |
| 32 | Heart failure is associated with accelerated age related metabolic bone disease | 0.9 | 9 | Citations (PDF) |
| 33 | The importance of developing hyperkalaemia in heart failure during long-term follow-up | 0.9 | 6 | Citations (PDF) |
| 34 | Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology | 4.7 | 497 | Citations (PDF) |
| 35 | Determinants of maximal dose titration of sacubitril/valsartan in clinical practice | 0.9 | 10 | Citations (PDF) |
| 36 | Cardiac device troubleshooting in the intensive care unit: an educational review | 0.9 | 0 | Citations (PDF) |
| 37 | Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low‐dose loop diuretic therapy | 4.7 | 13 | Citations (PDF) |
| 38 | Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial | 1.4 | 10 | Citations (PDF) |
| 39 | Reply to ‘Why mechanical dyssynchrony remains relevant to cardiac resynchronization therapy’ | 4.7 | 0 | Citations (PDF) |
| 40 | Patient profiling in heart failure for tailoring medical therapy. A consensus document of the
Heart Failure Association of the European Society of Cardiology | 4.7 | 252 | Citations (PDF) |
| 41 | Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care | 1.8 | 47 | Citations (PDF) |
| 42 | Left ventricular function recovery after ST-elevation myocardial infarction: correlates and outcomes | 1.4 | 13 | Citations (PDF) |
| 43 | Impact of Cardiac Resynchronization Therapy on Global and Cardiac Metabolism and Cardiac Mitochondrial Function | 0.9 | 7 | Citations (PDF) |
| 44 | The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial | 2.6 | 92 | Citations (PDF) |
| 45 | Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure | 0.9 | 15 | Citations (PDF) |
| 46 | 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy | 2.6 | 1,900 | Citations (PDF) |
| 47 | Renal sodium avidity, the prevailing renal target in heart failure | 2.6 | 11 | Citations (PDF) |
| 48 | The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department | 0.9 | 9 | Citations (PDF) |
| 49 | The value of urinary sodium assessment in acute heart failure | 0.9 | 33 | Citations (PDF) |
| 50 | COVID
‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology | 4.7 | 52 | Citations (PDF) |
| 51 | Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study | 1.9 | 34 | Citations (PDF) |
| 52 | ‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor | 1.9 | 124 | Citations (PDF) |
| 53 | Aetiology of Heart Failure, Rather than Sex, Determines Reverse LV Remodelling Response to CRT | 1.8 | 5 | Citations (PDF) |
| 54 | Indications and diagnostic yield of endomyocardial biopsies for unexplained cardiomyopathy, a single center experience | 0.9 | 6 | Citations (PDF) |
| 55 | Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes | 0.9 | 4 | Citations (PDF) |
| 56 | Reduced occurrence of appropriate therapy for ventricular arrhythmias after beta-blocker uptitration following implant of a primary prevention CRT-defibrillator | 0.9 | 3 | Citations (PDF) |
| 57 | The importance of dose optimisation in the treatment of iron deficiency in heart failure | 0.9 | 10 | Citations (PDF) |
| 58 | The Detrimental Effect of RA Pacing on LA Function and Clinical Outcome in Cardiac Resynchronization Therapy | 3.9 | 23 | Citations (PDF) |
| 59 | Evaluation of Kidney Function Throughout the Heart Failure Trajectory – A Position Statement from the Heart Failure Association of the European Society of Cardiology | 4.7 | 379 | Citations (PDF) |
| 60 | European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-Lowering Drugs in Patients with Heart Failure | 4.7 | 154 | Citations (PDF) |
| 61 | Heart Failure Association of the European Society of Cardiology Update on Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure | 4.7 | 77 | Citations (PDF) |
| 62 | Optimized Implementation of Cardiac Resynchronization Therapy: A Call for Action for Referral and Optimization of Care | 4.7 | 150 | Citations (PDF) |
| 63 | Impact of an Extended Audit on Identifying Heart Failure Patients in General Practice: Baseline Results of the OSCAR-HF Pilot Study | 1.9 | 15 | Citations (PDF) |
| 64 | Differences in Clinical Characteristics and Reported Quality of Life of Men and Women Undergoing Cardiac Resynchronization Therapy | 1.9 | 9 | Citations (PDF) |
| 65 | Digital Health Care Solution for Proactive Heart Failure Management with the Cordella Heart Failure System: Results of the SIRONA First-in-Human Study | 4.7 | 90 | Citations (PDF) |
| 66 | Impact of Sacubitril-Valsartan on Markers of Glomerular Function | 2.0 | 21 | Citations (PDF) |
| 67 | Acute heart failure | 37.9 | 521 | Citations (PDF) |
| 68 | Effects of Dapagliflozin on Congestion Assessed by Remote Pulmonary Artery Pressure Monitoring | 1.9 | 44 | Citations (PDF) |
| 69 | Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure: Beyond Glycaemic Control. A Position Paper of the Heart Failure Association of the European Society of Cardiology | 4.7 | 120 | Citations (PDF) |
| 70 | Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction | 1.3 | 5 | Citations (PDF) |
| 71 | Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure | 3.0 | 104 | Citations (PDF) |
| 72 | LA Mechanics in Decompensated Heart Failure | 3.9 | 78 | Citations (PDF) |
| 73 | Acute Coronary Syndromes and Acute Heart Failure: A Diagnostic Dilemma and High-Risk Combination. A Statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology | 4.7 | 87 | Citations (PDF) |
| 74 | Improved Cardiac and Venous Pressures During Hospital Stay in Patients with Acute Heart Failure: An Echocardiography and Biomarkers Study | 1.9 | 15 | Citations (PDF) |
| 75 | Association Between Loop Diuretic Dose Changes and Outcomes in Chronic Heart Failure: Observations from the ESC-EORP Heart Failure Long-Term Registry | 4.7 | 66 | Citations (PDF) |
| 76 | Diuretic Therapy for Patients With Heart Failure | 0.7 | 398 | Citations (PDF) |
| 77 | Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy | 0.7 | 56 | Citations (PDF) |
| 78 | Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction | 1.4 | 30 | Citations (PDF) |
| 79 | Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions | 0.9 | 23 | Citations (PDF) |
| 80 | General practitioners’ perceptions about their role in current and future heart failure care: an exploratory qualitative study | 1.6 | 23 | Citations (PDF) |
| 81 | CRT Optimization: What Is New? What Is Necessary? | 0.6 | 12 | Citations (PDF) |
| 82 | Rationale and Design of the IRON-CRT Trial: Effect of Intravenous Ferric Carboxymaltose on Reverse Remodelling Following Cardiac Resynchronization Therapy | 1.9 | 16 | Citations (PDF) |
| 83 | Initiation of Sacubitril/Valsartan in Haemodynamically Stabilised Heart Failure Patients in Hospital or Early After Discharge: Primary Results of the Randomised TRANSITION Study | 4.7 | 319 | Citations (PDF) |
| 84 | Acetazolamide to Increase Natriuresis in Congestive Heart Failure at High Risk for Diuretic Resistance | 4.7 | 110 | Citations (PDF) |
| 85 | Natriuretic Response Is Highly Variable and Associated With 6-Month Survival | 3.0 | 102 | Citations (PDF) |
| 86 | Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart Failure | 3.0 | 71 | Citations (PDF) |
| 87 | Atrial fibrillation screening with photo-plethysmography through a smartphone camera | 1.8 | 50 | Citations (PDF) |
| 88 | Heart Failure in Cardiomyopathies: A Position Paper from the Heart Failure Association of the European Society of Cardiology | 4.7 | 344 | Citations (PDF) |
| 89 | Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association | 13.1 | 1,306 | Citations (PDF) |
| 90 | Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction | 1.4 | 145 | Citations (PDF) |
| 91 | Cardiac resynchronization therapy pacemaker or cardiac resynchronization therapy defibrillator: what determines the choice?—findings from the ESC CRT Survey II | 1.8 | 20 | Citations (PDF) |
| 92 | The Optimal Plasma Volume Status in Heart Failure in Relation to Clinical Outcome | 0.9 | 38 | Citations (PDF) |
| 93 | The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of Cardiology | 4.7 | 1,032 | Citations (PDF) |
| 94 | Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patients | 0.9 | 23 | Citations (PDF) |
| 95 | Prevalence of Underlying Gastrointestinal Malignancies in Iron-Deficient Heart Failure | 1.9 | 21 | Citations (PDF) |
| 96 | Current animal models for the study of congestion in heart failure: an overview | 2.8 | 42 | Citations (PDF) |
| 97 | Optimising standards of care of heart failure in general practice the OSCAR-HF pilot study protocol | 0.9 | 5 | Citations (PDF) |
| 98 | Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome | 0.9 | 29 | Citations (PDF) |
| 99 | Exercise intervention in hospitalized heart failure patients, with emphasis on congestion-related complications: a review | 2.8 | 11 | Citations (PDF) |
| 100 | Endurance Exercise Intervention Is Beneficial to Kidney Function in a Rat Model of Isolated Abdominal Venous Congestion: a Pilot Study | 1.3 | 2 | Citations (PDF) |
| 101 | Insights Into Implementation of Sacubitril/Valsartan Into Clinical Practice | 1.9 | 55 | Citations (PDF) |
| 102 | Effects of Intravenous Home Dobutamine in Palliative End-Stage Heart Failure on Quality of Life, Heart Failure Hospitalization, and Cost Expenditure | 1.9 | 33 | Citations (PDF) |
| 103 | Protocol-driven remote monitoring of cardiac resynchronization therapy as part of a heart failure disease management strategy | 0.9 | 2 | Citations (PDF) |
| 104 | Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low | 0.9 | 16 | Citations (PDF) |
| 105 | Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure | 1.6 | 14 | Citations (PDF) |
| 106 | Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction | 0.9 | 160 | Citations (PDF) |
| 107 | Comprehensive In-Hospital Monitoring in Acute Heart Failure: Applications for Clinical Practice and Future Directions for Research. A Statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 4.7 | 73 | Citations (PDF) |
| 108 | Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology | 1.8 | 25 | Citations (PDF) |
| 109 | Value of routine investigations to predict loop diuretic down-titration success in stable heart failure | 1.6 | 26 | Citations (PDF) |
| 110 | Limited Contractile Reserve Contributes to Poor Peak Exercise Capacity in Iron-Deficient Heart Failure | 4.7 | 28 | Citations (PDF) |
| 111 | Endovascular shedding markers in patients with heart failure with reduced ejection fraction | 1.3 | 12 | Citations (PDF) |
| 112 | Selective abdominal venous congestion induces adverse renal and hepatic morphological and functional alterations despite a preserved cardiac function | 2.7 | 33 | Citations (PDF) |
| 113 | Rationale and Design of the Advor (Acetazolamide in Decompensated Heart Failure with Volume Overload) Trial | 4.7 | 89 | Citations (PDF) |
| 114 | Effect of multidisciplinary cardiac rehabilitation on the response to cardiac resynchronization therapy | 1.1 | 24 | Citations (PDF) |
| 115 | Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling | 2.5 | 33 | Citations (PDF) |
| 116 | Selective abdominal venous congestion to investigate cardiorenal interactions in a rat model | 1.5 | 13 | Citations (PDF) |
| 117 | The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction | 1.1 | 168 | Citations (PDF) |
| 118 | Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction | 2.7 | 24 | Citations (PDF) |
| 119 | Global myocardial oedema in advanced decompensated heart failure | 1.1 | 67 | Citations (PDF) |
| 120 | Leadless Left Ventricular Pacing | 0.7 | 7 | Citations (PDF) |
| 121 | Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications | 1.6 | 11 | Citations (PDF) |
| 122 | Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure | 0.7 | 119 | Citations (PDF) |
| 123 | Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions | 1.5 | 36 | Citations (PDF) |
| 124 | Heart Failure with Myocardial Recovery - The Patient Whose Heart Failure Has Improved: What Next? | 5.0 | 30 | Citations (PDF) |
| 125 | Organ Dysfunction, Injury and Failure in Acute Heart Failure: From Pathophysiology to Diagnosis and Management. A Review on Behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | 4.7 | 370 | Citations (PDF) |
| 126 | Renal sodium avidity in heart failure: from pathophysiology to treatment strategies | 2.6 | 192 | Citations (PDF) |
| 127 | Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy | 0.9 | 38 | Citations (PDF) |
| 128 | Rationale and Design of the Adaptresponse Trial: A Prospective Randomized Study of Cardiac Resynchronization Therapy with Preferential Adaptive Left Ventricular-Only Pacing | 4.7 | 36 | Citations (PDF) |
| 129 | Intrarenal Flow Alterations During Transition From Euvolemia to Intravascular Volume Expansion in Heart Failure Patients | 3.0 | 143 | Citations (PDF) |
| 130 | SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys | 2.0 | 15 | Citations (PDF) |
| 131 | Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure | 0.9 | 21 | Citations (PDF) |
| 132 | Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy | 1.5 | 35 | Citations (PDF) |
| 133 | Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy | 5.4 | 27 | Citations (PDF) |
| 134 | Subclinical volume overload in stable outpatients with chronic heart failure | 0.9 | 2 | Citations (PDF) |
| 135 | Is venous congestion associated with reduced cerebral oxygenation and worse neurological outcome after cardiac arrest? | 4.1 | 32 | Citations (PDF) |
| 136 | Contemporary Management of Acute Right Ventricular Failure: A Statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology | 4.7 | 650 | Citations (PDF) |
| 137 | Mode of Death in Octogenarians Treated With Cardiac Resynchronization Therapy | 0.9 | 21 | Citations (PDF) |
| 138 | Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure | 2.7 | 99 | Citations (PDF) |
| 139 | Management of Cardio-Renal Syndrome and Diuretic Resistance | 0.6 | 42 | Citations (PDF) |
| 140 | Cardiac Resynchronization Therapy With a Quadripolar Electrode Lead Decreases Complications at 6 Months | 2.4 | 42 | Citations (PDF) |
| 141 | Transient Hyponatremia During Hospitalization for Acute Heart Failure | 1.6 | 26 | Citations (PDF) |
| 142 | Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload | 0.9 | 87 | Citations (PDF) |
| 143 | Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response | 0.9 | 3 | Citations (PDF) |
| 144 | Response and Tolerance to Oral Vasodilator Up-Titration After Intravenous Vasodilator Therapy in Advanced Decompensated Heart Failure | 4.7 | 8 | Citations (PDF) |
| 145 | Prognostic Role of Cardiac Power Index in Ambulatory Patients with Advanced Heart Failure | 4.7 | 50 | Citations (PDF) |
| 146 | Mitral Valve Area During Exercise After Restrictive Mitral Valve Annuloplasty | 0.7 | 43 | Citations (PDF) |
| 147 | The Pathophysiological Role of Interstitial Sodium in Heart Failure | 0.7 | 163 | Citations (PDF) |
| 148 | Hyponatremia in Acute Decompensated Heart Failure | 0.7 | 150 | Citations (PDF) |
| 149 | Pulmonary Vascular Response to Exercise in Symptomatic Heart Failure with Reduced Ejection Fraction and Pulmonary Hypertension | 4.7 | 20 | Citations (PDF) |
| 150 | SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes? | 1.2 | 8 | Citations (PDF) |
| 151 | A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure | 1.8 | 55 | Citations (PDF) |
| 152 | Current Approach to Decongestive Therapy in Acute Heart Failure | 2.0 | 54 | Citations (PDF) |
| 153 | The Kidney in Congestive Heart Failure: ‘are Natriuresis, Sodium, and Diuretics Really the Good, the Bad and the Ugly?’ | 4.7 | 160 | Citations (PDF) |
| 154 | Asymptomatic episodes of device-registered atrial tachyarrhythmia are not associated with worse cardiac resynchronization therapy response | 1.8 | 5 | Citations (PDF) |
| 155 | Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction | 2.7 | 90 | Citations (PDF) |
| 156 | Tricuspid annuloplasty concomitant with mitral valve surgery: Effects on right ventricular remodeling | 2.0 | 58 | Citations (PDF) |
| 157 | Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated With Poor Long-Term Outcomes in Acute Decompensated Heart Failure | 0.9 | 158 | Citations (PDF) |
| 158 | The Acute Cardiorenal Syndrome: Burden and Mechanisms of Disease | 2.0 | 15 | Citations (PDF) |
| 159 | Prognostic Value of Glomerular Filtration Changes Versus Natriuretic Response in Decompensated Heart Failure With Reduced Ejection | 0.9 | 19 | Citations (PDF) |
| 160 | The diagnostic accuracy of the MyDiagnostick to detect atrial fibrillation in primary care | 2.8 | 80 | Citations (PDF) |
| 161 | Etiology and Relevance of the Figure-of-Eight Artifact on Echocardiography after Percutaneous Left Atrial Appendage Closure with the Amplatzer Cardiac Plug | 2.2 | 15 | Citations (PDF) |
| 162 | Implementation of transmural disease management in patients admitted with advanced heart failure | 0.9 | 6 | Citations (PDF) |
| 163 | The polycompartment syndrome: a concise state-of-the-art review | 0.9 | 95 | Citations (PDF) |
| 164 | Abdominal Contributions to Cardiorenal Dysfunction in Congestive Heart Failure | 0.7 | 379 | Citations (PDF) |
| 165 | Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy | 1.8 | 25 | Citations (PDF) |
| 166 | Novel Urinary Biomarkers in Detecting Acute Kidney Injury, Persistent Renal Impairment, and All-Cause Mortality Following Decongestive Therapy in Acute Decompensated Heart Failure | 0.9 | 79 | Citations (PDF) |
| 167 | Uptitration of Renin-Angiotensin System Blocker and Beta-Blocker Therapy in Patients Hospitalized for Heart Failure With Reduced Versus Preserved Left Ventricular Ejection Fractions | 1.5 | 26 | Citations (PDF) |
| 168 | Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response | 2.6 | 18 | Citations (PDF) |
| 169 | Determinants of Dynamic Changes in Serum Creatinine in Acute Decompensated Heart Failure: The Importance of Blood Pressure Reduction During Treatment | 4.7 | 107 | Citations (PDF) |
| 170 | Cardiac resynchronization therapy with or without defi brillator: experience from a high-volume Belgian implantation centre | 0.9 | 5 | Citations (PDF) |
| 171 | New Insights into Combinational Drug Therapy to Manage Congestion in Heart Failure | 2.0 | 23 | Citations (PDF) |
| 172 | Combined management of atrial fibrillation and heart failure: case studies | 2.8 | 1 | Citations (PDF) |
| 173 | Prognostic Role of Pulmonary Arterial Capacitance in Advanced Heart Failure | 2.7 | 163 | Citations (PDF) |
| 174 | Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration | 0.7 | 101 | Citations (PDF) |
| 175 | Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling | 0.9 | 36 | Citations (PDF) |
| 176 | Impact of Left Ventricular Remodeling on Diagnostic and Prognostic Value of Tissue Doppler Indices in Chronic Systolic Heart Failure | 0.9 | 9 | Citations (PDF) |
| 177 | Retrograde approach for revascularization of a coronary chronic total occlusion with review of literature | 0.9 | 0 | Citations (PDF) |
| 178 | Optimizing Cardiac Resynchronization Therapy in Advanced Heart Failure | 2.3 | 11 | Citations (PDF) |
| 179 | Importance of Adjunctive Heart Failure Optimization Immediately After Implantation to Improve Long-Term Outcomes With Cardiac Resynchronization Therapy | 1.5 | 60 | Citations (PDF) |
| 180 | Impact of Systemic Venous Congestion in Heart Failure | 2.0 | 107 | Citations (PDF) |
| 181 | Insights From Internet‐Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program | 2.3 | 17 | Citations (PDF) |
| 182 | Right Ventricular Response to Intensive Medical Therapy in Advanced Decompensated Heart Failure | 2.7 | 97 | Citations (PDF) |
| 183 | Cardiorenal syndrome in decompensated heart failure | 2.6 | 120 | Citations (PDF) |
| 184 | Tissue Doppler Imaging in the Estimation of Intracardiac Filling Pressure in Decompensated Patients With Advanced Systolic Heart Failure | 13.1 | 412 | Citations (PDF) |
| 185 | Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure | 1.5 | 45 | Citations (PDF) |
| 186 | Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure | 0.7 | 1,605 | Citations (PDF) |
| 187 | Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure | 0.7 | 72 | Citations (PDF) |
| 188 | Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program | 0.7 | 469 | Citations (PDF) |
| 189 | Prognostic Evaluation of Ambulatory Patients With Advanced Heart Failure | 1.5 | 29 | Citations (PDF) |
| 190 | Gender Differences in Patients Admitted With Advanced Decompensated Heart Failure | 1.5 | 23 | Citations (PDF) |
| 191 | Myocardial Gene Expression in Heart Failure Patients Treated With Cardiac Resynchronization Therapy | 0.7 | 163 | Citations (PDF) |
| 192 | Elevated Intra-Abdominal Pressure in Acute Decompensated Heart Failure | 0.7 | 419 | Citations (PDF) |
| 193 | Sodium Nitroprusside for Advanced Low-Output Heart Failure | 0.7 | 213 | Citations (PDF) |
| 194 | Collapse of three cardiac chambers due to a pericardial effusion | 1.6 | 2 | Citations (PDF) |
| 195 | Myotomy through heart-port access for myocardial bridging | 1.6 | 8 | Citations (PDF) |
| 196 | Endomyocardial Upregulation of β1 Adrenoreceptor Gene Expression and Myocardial Contractile Reserve Following Cardiac Resynchronization Therapy | 0.9 | 40 | Citations (PDF) |
| 197 | Prompt Reduction in Intra-Abdominal Pressure Following Large-Volume Mechanical Fluid Removal Improves Renal Insufficiency in Refractory Decompensated Heart Failure | 0.9 | 174 | Citations (PDF) |
| 198 | Early and late effects of cardiac resynchronization therapy on force–frequency relation and contractility regulating gene expression in heart failure patients | 1.8 | 67 | Citations (PDF) |
| 199 | Mechanical dyssynchrony in advanced decompensated heart failure: Relation to hemodynamic responses to intensive medical therapy | 1.8 | 10 | Citations (PDF) |
| 200 | Current trends in recipient selection for heart transplantation | 1.3 | 1 | Citations (PDF) |
| 201 | Using echocardiography in cardiac resynchronization therapy | 1.8 | 21 | Citations (PDF) |
| 202 | Pneumopericardium after pericardiocentesis | 1.6 | 18 | Citations (PDF) |
| 203 | Migration of two venous stents into the right ventricle in a patient with May–Thurner syndrome | 1.6 | 29 | Citations (PDF) |
| 204 | The Eustachian valve in pulmonary embolism: Rescue or perilous? | 2.1 | 7 | Citations (PDF) |
| 205 | Multiple exercise induced syncopal episodes in a young woman due to arrhythmogenic right ventricular dysplasia | 1.8 | 0 | Citations (PDF) |
| 206 | Severe coronary artery spasm after administration of a 5-hydroxytryptamine type 1 receptor agonist in a patient with new-onset Graves’ disease and myocarditis after SARS-CoV2 vaccination | 0.9 | 3 | Citations (PDF) |
| 207 | Empagliflozin in heart failure with preserved ejection fraction: from randomized trials to real-world evidence | 0.9 | 6 | Citations (PDF) |
| 208 | Heart Failure 2025 Congress: a recent remarkable success in heart failure | 2.6 | 0 | Citations (PDF) |
| 209 | Real-world improved, remission, and recovered heart failure: long-term follow-up outcomes | 4.7 | 0 | Citations (PDF) |
| 210 | Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper | 1.9 | 1 | Citations (PDF) |
| 211 | Implementation of guideline-directed medical therapy in patients with heart failure and obesity:
European Journal of Heart Failure
expert consensus document | 4.7 | 2 | Citations (PDF) |
| 212 | Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease | 2.0 | 1 | Citations (PDF) |
| 213 | Comprehensive evaluation of hypertrophic cardiomyopathy: European Journal of Heart Failure expert consensus document | 4.7 | 0 | Citations (PDF) |
| 214 | Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors | 1.9 | 0 | Citations (PDF) |
| 215 | Resynchronising care: addressing sex differences in cardiac resynchronisation therapy | 6.6 | 0 | Citations (PDF) |
| 216 | From Loop Diuretics to Closed-Loop Decongestion | 3.0 | 0 | Citations (PDF) |
| 217 | Assessing Organ Perfusion Pressures in Patients With Advanced Heart Failure and Venous Congestion 0, , | | 0 | Citations (PDF) |
| 218 | Refining the Role of Beta-Blockers in Cardiovascular Medicine | 0.7 | 0 | Citations (PDF) |
| 219 | Implementation opportunities for sodium-glucose Co-transporter-2 inhibitors in the Belgian heart failure landscape | 0.9 | 1 | Citations (PDF) |
| 220 | High-probability heart failure with preserved ejection fraction phenotype in atrial fibrillation patients undergoing ablation: insights from RECAP | 1.8 | 0 | Citations (PDF) |
